

1-1-2012

# BMP3 Suppresses Osteoblast Differentiation of Bone Marrow Stromal Cells Via Interaction With Acvr2b.

Shoichiro Kokabu

Laura Gamer

Karen Cox

Jonathan W. Lowery Ph.D.  
Marian University - Indianapolis, [jlowery@marian.edu](mailto:jlowery@marian.edu)

Kunikazu Tsuji

*See next page for additional authors*

Follow this and additional works at: [http://mushare.marian.edu/com\\_fp](http://mushare.marian.edu/com_fp)

 Part of the [Cells Commons](#), and the [Genetics and Genomics Commons](#)

## Recommended Citation

Kokabu S, Gamer L, Cox K, Lowery JW, Kunikazu T, Econimedes A, Katagiri T, Rosen V. "BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b." *Mol Endocrinol*. 2012;26(1):87-94. PMC3248326. PMID: 22074949.

This Article is brought to you for free and open access by the College of Osteopathic Medicine at MUShare. It has been accepted for inclusion in Faculty Publications and Research by an authorized administrator of MUShare. For more information, please contact [emandity@marian.edu](mailto:emandity@marian.edu).

---

**Authors**

Shoichiro Kokabu, Laura Gamer, Karen Cox, Jonathan W. Lowery Ph.D., Kunikazu Tsuji, Regina Raz, Aris Economides, Takenobu Katagiri, and Vicki Rosen

## BMP3 Suppresses Osteoblast Differentiation of Bone Marrow Stromal Cells via Interaction with Acvr2b

Shoichiro Kokabu, Laura Gamer, Karen Cox, Jonathan Lowery, Kunikazu Tsuji, Regina Raz, Aris Economides, Takenobu Katagiri, and Vicki Rosen

Department of Developmental Biology (S.K., L.G., K.C., J.L., V.R.), Harvard School of Dental Medicine, Boston, Massachusetts 02115; Section of Orthopedic Surgery (K.T.), Tokyo Medical and Dental University, Tokyo 113-8510, Japan; Regeneron Pharmaceuticals (R.R., A.E.), Tarrytown, New York 10591; and Division of Pathophysiology (T.K.), Saitama Medical University, Saitama 359-8513, Japan

Enhancing bone morphogenetic protein (BMP) signaling increases bone formation in a variety of settings that target bone repair. However, the role of BMP in the maintenance of adult bone mass is not well understood. Targeted disruption of BMP3 in mice results in increased trabecular bone formation, whereas transgenic overexpression of BMP3 in skeletal cells leads to spontaneous fracture, consistent with BMP3 having a negative role in bone mass regulation. Here we investigate the importance of BMP3 as a mediator of BMP signaling in the adult skeleton. We find that osteoblasts (OBL) and osteocytes are the source of BMP3 in adult bone. Using *in vitro* cultures of primary bone marrow stromal cells, we show that overexpression of BMP3 suppresses OBL differentiation, whereas loss of BMP3 increases colony-forming unit fibroblasts and colony-forming unit OBL. The ability of BMP3 to affect OBL differentiation is due to its interaction with activin receptor type 2b (Acvr2b) because knockdown of endogenous Acvr2b in bone marrow stromal cells reduces the suppressive effect of BMP3 on OBL differentiation. These findings best fit a model in which BMP3, produced by mature bone cells, acts to reduce BMP signaling through Acvr2b in skeletal progenitor cells, limiting their differentiation to mature OBL. Our data further support the idea that endogenous BMPs have a physiological role in regulating adult bone mass. (*Molecular Endocrinology* 26: 87–94, 2012)

**B**one morphogenetic proteins (BMP) were identified as signals that induce ectopic bone formation through effects on skeletal progenitor cells present in adult animals (1). In rodents, cellular targets for BMP include periosteal cells, muscle satellite cells, vessel pericytes, and bone marrow stromal cells (BMSC) (2–6). BMP signaling is initiated when dimeric ligands associate with type I and type II receptors that are transmembrane serine/threonine kinases, forming a multimeric receptor ligand complex. Within this complex, the constitutively activated type II receptors serve a regulatory function by phosphorylating type I receptors. The importance of type II receptor control of BMP signaling is reinforced by the recent finding that fibrodysplasia ossificans progressiva, a genetic disorder of uncontrolled endochondral ossification in soft tissue,

is caused by a mutation that renders Alk2, a type I BMP receptor, constitutively active and removed from regulation by type II receptor (7, 8). Once activated, type I receptors propagate BMP signals by phosphorylating BMP-specific R-Smad1, -5, and -8 (canonical BMP signaling), and also by phosphorylating MAPK such as Erk, Jnk, and p38 (noncanonical BMP signaling) (9). Phosphorylated R-Smad form heteromeric complexes with Smad4 and directly activate the transcription of BMP-responsive genes (10, 11).

Although BMP have been successfully developed as clinical tools for enhancing bone formation during tissue regeneration, the potential of endogenous BMP signaling to regulate bone mass is less well understood (12). Recent studies employing administration of neutralizing anti-

ISSN Print 0888-8809 ISSN Online 1944-9917  
Printed in U.S.A.

Copyright © 2012 by The Endocrine Society

doi: 10.1210/me.2011-1168 Received June 30, 2011. Accepted October 17, 2011.

First Published Online November 10, 2011


Abbreviations: Acvr2b, Activin receptor type 2b; ALP, alkaline phosphatase; BMP, bone morphogenetic protein; BMSC, bone marrow stem cell; CFU-F, colony-forming unit fibroblast; CFU-OB, colony-forming unit osteoblast; OBL, osteoblast; OCY, osteocyte; RNAi, RNA interference; siRNA, small interfering RNA; TCA, trichloroacetic acid.

bodies or soluble receptor decoys found reducing the availability of TGF- $\beta$  or activin leads to significant gains in bone formation, identifying these factors as negative regulators of adult bone mass (13–16). In contrast, enhanced BMP signaling appears to play a positive role, because reducing the levels of the BMP antagonists noggin or gremlin enhances bone formation in the adult skeleton (17, 18). BMP3, a receptor antagonist specific for the type II receptor activin receptor type 2b (Acvr2b), appears to serve a unique role in the adult skeleton. Adult mice lacking BMP3 have increased bone mass, whereas mice with increased BMP3 levels in bone show delayed endochondral ossification with spontaneous rib fractures (19, 20). However, the cellular targets of BMP3 and the molecular mechanisms used by BMP3 to affect bone formation remain to be completely elucidated. In the present study, we use a LacZ knock-in allele to the BMP3 locus (BMP3 LacZ knock-in) to identify osteoblasts (OBL) and osteocytes (OCY) as the bone cells responsible for BMP3 production in the adult skeleton. We show that BMP3 targets osteoprogenitor cells where it inhibits BMP signaling. We define the interaction of BMP3/Acvr2b as a key event in BMP-mediated OBL differentiation by demonstrating that knockdown of endogenous Acvr2b diminishes the suppressive effect of BMP3 on osteoprogenitor cells. In addition, we find that loss of BMP3 increases colony-forming unit fibroblasts (CFU-F) and colony-forming unit OBL (CFU-OB) in BMSC cultures. Taken together, these data confirm that BMP3, secreted by OBL and OCY, regulates trabecular bone formation by regulating the differentiation of BSMC, thus identifying BMP3 as a novel target for bone mass augmentation.

## Results

### BMP3 is expressed by OBL and OCY


Using Velocigene technology (21), a BMP3-null mouse was generated where the first exon (encoding the N-terminal part of the precursor region) was replaced in frame with the *lacZ* reporter gene (BMP3 LacZ knock-in). To examine skeletal expression of BMP3, we analyzed heterozygous mice at 4 wk of age and found that OBL and OCY are the source of BMP3 in adult bone (Fig. 1). These data are in agreement with profiling data from Paic *et al.* (21) who reported that BMP3 as well as Acvr2b transcripts were present in OBL and OCY. We did not find BMP3 expression in cartilage, osteoclasts, or skeletal progenitor cells including those of the bone marrow stroma or the outer layers of the periosteum, consistent with the idea that BMP3 is a product of mature OBL lineage cells (Fig. 1 and data not shown).



**FIG. 1.** OBL and OCY express BMP3. Tibia from BMP3 4-wk-old LacZ knock-in mice stained for  $\beta$ -galactosidase. Diaphyseal region is shown in the top panel. The boxed areas in the upper panel are shown as magnified images ( $\times 20$ ) of cortical bone (CB) and trabecular bone (TB) in lower panels. Arrowheads and arrows indicate OBL and OCY, respectively. BM, Bone marrow; PO, periosteum.

### BMP3 inhibits Smad signaling and suppresses OBL differentiation

We next wanted to determine the effects of BMP3 on skeletal progenitor cell differentiation *in vitro*. As a source for BMP3 protein, we transfected W20-17 cells with BMP3 expression vectors. W20-17 cells are an osteoprogenitor cell line that requires BMP signaling for OB differentiation (2). Conditioned medium from W20-17 cells transfected with control or BMP3 containing pcDEF3 expression vectors were analyzed by Western blot, and BMP3 expression was verified (Fig. 2A). We then examined the effects of overexpression of BMP3 in skeletal progenitor cells and found that it suppressed the osteogenic activity of BMP4 and BMP2 in all cells examined including W20-17 (Fig. 2, B and C); ST2, a mouse bone marrow stromal cell line (Fig. 2D); and primary BSMC (Fig. 2E). Furthermore, BMP3 also suppressed expression of osteocalcin, a marker of mature OBL in cells treated with osteogenic BMP (Fig. 2F). To determine whether the inhibitory effects of BMP3 target canonical BMP signaling, we analyzed phosphorylation of endoge-



**FIG. 2.** BMP3 suppresses OBL differentiation induced by BMP in osteoprogenitor cells. A, Western blot of conditioned medium from W20-17 cells transfected with empty vector or BMP3 verifies BMP3 expression. B and C, W20-17 cells were transfected with empty vector or BMP3, and then ALP activity was stimulated by cotransfection with BMP2 or BMP4. BMP3 significantly reduced the BMP-induced ALP activity. D and E, ST2 cells and primary BSMC that had been transfected with BMP4 to stimulate ALP activity were treated with control (vector) or BMP3-conditioned medium from W20-17 cells. BMP3-conditioned medium reduced ALP activity in both cell types. F, W20-17 cells cotransfected with BMP3 and BMP4 expressed reduced levels of osteocalcin (OC) on d 3, as determined by quantitative real time PCR analysis. Data are shown as the mean  $\pm$  SD ( $n = 3$ ). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  in comparison with cells transfected or treated with an empty vector (Vec) or conditioned medium from empty vector-transfected cells in each group.


nous Smad1/5/8 by Western blotting and activation of the IdWTF4 BMP-responsive reporter in W20-17 cells. Although transfection of cells with BMP4 or BMP2 resulted in increased p-Smad1/5/8 levels and robustly activated IdWTF4-luc, coexpression of BMP3 reduced BMP4-induced phosphorylation of Smad1/5/8 (Fig. 3A) and also suppressed IdWT4F-luc reporter activity induced by co-

expression of BMP4 (Fig. 3B) or BMP2 (Fig. 3C) in a dose-dependent manner. BMP3 appeared to directly suppress BMP signaling and not act by changing levels of BMP antagonists, because transcript levels for chordin, noggin, and gremlin were not altered in mouse BSMC treated with BMP3-conditioned media (data not shown).


### Suppressive effects of BMP3 on OBL differentiation require *Acvr2b*

We previously reported that BMP3 interferes with BMP signaling by binding to the multifunctional type II BMP/activin receptor *Acvr2b* (22). Allendorph *et al.* (23) confirmed these data by showing that BMP3 receptor specificity for *Acvr2b* is controlled through the interaction of lysine 30 of BMP3 and glutamic acid 76 of *Acvr2b*. To investigate whether BMP3 suppresses OB differentiation via its specific interaction with *Acvr2b*, we examined the effects of BMP3 on cells in which endogenous *Acvr2b* had been knocked down using small interfering RNA (siRNA). As a first step, we confirmed that W20-17 cells express *Acvr2b* and

found that *Acvr2b* is the most abundant type II BMP receptor in these cells (Fig. 4A). We next confirmed that transfection of W20-17 cells with siRNA specific for *Acvr2b* significantly reduced protein levels of endogenous *Acvr2b* in Western blots (60% knockdown) when compared with control/scrambled RNA oligonucleotides (Fig.



**FIG. 3.** BMP3 suppresses BMP-Smad signaling. A, W20-17 cells were cotransfected with empty vector or BMP3 along with BMP4. At 24 h after transfection, protein levels were determined by Western blot. The protein levels were quantified by using Image J software. Smad1 was used for protein normalization. BMP3 reduced the amount of phospho- (P-)Smad1/5/8 induced by BMP4. B and C, W20-17 cells were cotransfected with 0, 30, 60, or 90 ng BMP3 expression vector or 0, 30, 60, or 90 ng empty vector along with 45 ng IdWT4F-luc reporter and 15 ng phRL-SV40 internal control vector. Luciferase activity was then stimulated by transfection of 50 ng BMP4 expression vector (B) or 50 ng BMP2 expression vector (C). BMP3 was able to reduce the luciferase activity induced by both BMP4 and BMP2. Data are shown as the mean  $\pm$  SD ( $n = 3$ ). \*\*,  $P < 0.01$  in comparison with cells transfected with an empty vector and BMP4 or BMP2 in each group.



**FIG. 4.** BMP3 suppresses BMP signaling via Acvr2b. A, Transcript levels of *BMPRII*, *Acvr2a*, and *Acvr2b* were determined in W20-17 cells using quantitative real-time PCR. B–D, W20-17 cells were transfected with siRNA specific for Acvr2b or a scrambled siRNA. B, Western blot analysis on 1 shows the level of endogenous Acvr2b was reduced 60% using siRNA for Acvr2b. The protein levels were quantified by using Image J software.  $\beta$ -Actin was used for protein normalization. The siRNA specific for Acvr2b reduced the suppressive effect of BMP3 on IdWT4F-luc activity (C) and ALP activity (D) induced by BMP4 in W20-17 cells. E, Transcript levels of *BMPRII*, *Acvr2a*, and *Acvr2b* were determined in C2C12 cells by quantitative real-time PCR. F, Cotransfection of BMP3 did not suppress ALP activity induced by cotransfection of BMP2 in C2C12 cells. Data are shown as the mean  $\pm$  SD ( $n = 3$ ). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .

4B). We then tested the ability of BMP3 to reduce BMP4-mediated IdWT4F-luc and alkaline phosphatase (ALP) activation in the Acvr2b knockdown cells. We found that BMP3 could no longer block BMP4 activation of the BMP luciferase reporter (Fig. 4C) or induction of ALP activity (Fig. 4D), consistent with the finding that BMP3 binds and acts specifically through Acvr2b (24, 25). To confirm our RNA interference (RNAi) studies, we used C2C12 cells, which have been reported to lack expression of Acvr2b and should prevent them from being targeted by BMP3 (23–25). Although we detected low levels of *Acvr2b* by quantitative PCR in our C2C12 cells (Fig. 4E), we found that BMP3 was unable to block ALP activity induced by BMP treatment (Fig. 4F). Taken together, these findings confirm that the suppressive effect of BMP3 on OBL differentiation requires Acvr2b.


#### Absence of BMP3 increases CFU-F and CFU-OB from BMSC

If endogenous BMP3 functions to regulate OBL differentiation from BMSC, then mice lacking BMP3 should have an enhanced basal level of OBL differentiation. To

investigate this idea, we harvested BMSC from BMP3-null mice and wild-type littermates and tested these cells in standard CFU-F and CFU-OB assays. BMSC that reside in a BMP3-null environment show an increase in CFU-F colony number and colony size (Fig. 5, A and B). In addition, the number of ALP-positive colonies produced by BMSC from mice lacking BMP3 and their spontaneous differentiation into OBL-lineage cells was significantly increased in the absence of exogenous osteogenic signals when compared with wild-type controls (Fig. 5, C and D). These data confirm that loss of BMP3 results in increased differentiation of early OBL precursors into mature OBL and further suggest a negative role for BMP3 in adult bone.


#### Discussion

In the present study, we examined the cellular targets and molecular mechanisms that underlie the inhibition of BMP-induced OBL differentiation by BMP3, leading to the high-bone-mass phenotype in the BMP3 knockout



**FIG. 5.** Absence of BMP3 increases CFU-F and CFU-OB in BMSC cultures. BMSC were plated in six-well plates at two different densities ( $1.0 \times 10^6$  or  $1.5 \times 10^6$  cells per well). CFU-F (A) and cell number per colony (B) were evaluated after 10 d culture using methylene green staining. BSMC from BMP3<sup>-/-</sup> mice had increased CFU-F colony number and colony size when compared with wild-type (WT) controls. The appearance of CFU-OB was assessed by ALP (C) and alizarin red staining (D) after 10 or 28 d, respectively. The density of ALP staining was quantified by using Image J software. The number of ALP- and alizarin red-positive colonies was increased in BSMC from BMP3<sup>-/-</sup> mice when compared with wild-type control mice. \*,  $P < 0.05$ .

mice (19, 22, 23). We demonstrate that this inhibition is due to the interaction of BMP3 with the type II receptor, Acvr2b, present on skeletal progenitor cells. BMP3/Acvr2b binding occurs upstream of type I receptor function, an idea confirmed by the observation that over-expression of BMP3 could not suppress IdWT4F-luc ac-



**FIG. 6.** Model for BMP3 control of BMSC differentiation in the bone marrow microenvironment. BMP3 produced by OBL and OCY interacts with Acvr2b present on BMSC to suppress OBL differentiation and maturation induced by BMP. In addition, because OBL and OCY express Acvr2b, BMP3 may also effect BMP signaling and gene expression in these cells as a means of regulating adult bone mass.

tivity induced by a constitutively active Smad1 (Supplemental Fig. 1, published on The Endocrine Society's Journals Online web site at <http://mend.endojournals.org>) and in agreement with results obtained previously in *Xenopus* embryo studies (22). These data suggest an important regulatory role for type II BMP receptors in the process of bone formation in the adult skeleton, an idea supported by the pathological endochondral ossification that occurs when type II receptor control is bypassed in fibrodysplasia ossificans progressiva (7, 8).

Our results show that in adult bone, BMP3 is produced by OBL and OCY. Removing BMP3 from the bone environment increased CFU-F colony number and colony size as well as the spontaneous differentiation of osteoprogenitors into bone-forming cells. These data suggest a model of BMP3 activity in the skeleton whereby BMP3 produced by mature bone cells acts to limit the differentiation of Acvr2b-positive osteoprogenitors residing in the bone marrow microenvironment (Fig. 6). Osteoprogenitors not only express Acvr2b but also have other type II receptors (Acvr2a, BMPR-II, and transforming growth factor beta type II receptor) that are used by BMP/TGF- $\beta$ /activin ligands to regulate signal transduction in bone. This fact is highlighted by recent data showing that systemic administration of a TGF- $\beta$  neutralizing antibody to adult mice increased bone mass and bone density, suggesting that TGF- $\beta$  signaling via transforming growth factor beta type II receptor on BMSC limits osteogenesis (13, 14, 26). In addition, systemic administration of AR2AFc (soluble activin type II A receptor) and AR2BFc (soluble activin type II B receptor) type II activin receptor decoys also increases bone mass *in vivo*, and administration of AR2AFc to BMP3-null mice further increases bone mineral density (15, 16, 27). Taken as a whole, these data point to the potential therapeutic benefits of increasing bone formation through modulating the interactions between type II receptors and BMP/TGF- $\beta$ /activins and suggest that BMP3 and its specific interaction with Acvr2b may be a novel means to enhance osteogenesis.

enhance osteogenesis.

## Materials and Methods

### Animals

BMP3<sup>-/-</sup> mice were previously generated and described elsewhere (19). BMP3 LacZ knock-in mice were generated at Regeneron Pharmaceuticals using Velocigene technology (28). The region of the BMP3 gene containing exon 1 was deleted and replaced with a transmembrane-lacZ/neo

cassette using bacterial homologous recombination. All studies performed were approved by the Institutional Animal Care and Use Committee at Harvard Medical School (Boston, MA).

### X-gal staining

Tibias were collected from 4-wk-old BMP3 LacZ knock-in mice and littermate controls. Tissues were fixed for 24 h at 4 C in 4% paraformaldehyde/PBS (pH 8), decalcified at 4 C in 0.5 M EDTA (pH 7.4) for 10–14 d, equilibrated in 15% sucrose for 1 h, 30% sucrose overnight at 4 C, and cryo-embedded. For X-gal staining, 20- $\mu$ m sections were postfixed in 4% paraformaldehyde, washed three times for 15 min in 2 mM MgCl<sub>2</sub>, 0.01% sodium deoxycholate, 0.02% Nonidet P-40 in PBS, stained overnight in 0.1% X-gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide in PBS (pH 8) overnight at 37 C, and counterstained with eosin/floxin (29).

### Plasmids

Plasmids encoding wild-type human BMP3 (accession number NM\_001201.2) were obtained by a standard RT-PCR technique using PrimeSTAR HS DNA polymerase (TaKaRa, Ohtsu, Japan) and cloned into a pcDEF3 expression vector (30). The human BMP2, BMP4, mouse constitutively active Smad1, and IdWT4F-luc reporter plasmids have been previously described (10, 31).

### Cell culture and transfection

W20-17 cells were cultured and maintained as described previously (2). ST2 cells were purchased from the RIKEN Cell Bank (Tsukuba, Japan). ST2 cells were cultured and maintained in  $\alpha$ -MEM supplemented with 10% fetal bovine serum. Primary BSMC were collected from femurs and tibias of 6-wk-old wild-type C57BL/6J mice or BMP3<sup>-/-</sup> mice. After epiphyses were removed, bone was flushed with 15 ml  $\alpha$ -MEM using a 20-ml syringe fitted with a 23-gauge needle. Flushed bone marrow cells were cultured with  $\alpha$ -MEM containing 15% fetal bovine serum for 4 d (32). Cells were transfected with plasmids using Lipofectamine 2000 (Invitrogen) (33). Conditioned media were collected from W20-17 cells 3 d after transfection with empty vector, BMP3, or BMP4 for each assay.

### ALP and luciferase assays

ALP activity was measured as a marker of OBL differentiation on d 2. Cells treated with an acetone/ethanol (50:50) mixture were incubated with a substrate solution composed of 0.1 M diethanolamine, 1 mM MgCl<sub>2</sub>, and 1 mg/ml *p*-nitrophenylphosphate. The reaction was terminated by adding 3 M NaOH, and absorbance values were measured at 405 nm (34, 35). Luciferase assays were performed using IdWT4F-luc, phRL-SV40 (Promega, Madison, WI) with the Dual-Glo Luciferase Assay System (Promega) (36).

### CFU-F and CFU-OB assay

Primary BSMC were plated in triplicate cultures (six-well plates) at two different densities ( $1.0 \times 10^6$  or  $1.5 \times 10^6$  cells per well). The formation of CFU-F and CFU-OB was evaluated after 10 and 28 d of culture. At the end of each experiment, cultures were washed twice with PBS and fixed with cold ethanol, and CFU-F were stained with methylene green, and colonies with more than 50 cells were counted. For CFU-OB assays, forma-

tion of OBL progenitors and OBL was detected using ALP and alizarin red staining (37). For ALP staining, cells were incubated for 20 min with a mixture of 0.1 mg/ml naphthol AS-MX phosphate (Sigma-Aldrich Chemicals, St. Louis, MO), 0.5% *N,N*-dimethylformamide, 2 M MgCl<sub>2</sub>, and 0.6 mg/ml fast red TR salt (Sigma-Aldrich) in 0.1 M Tris-HCl (pH 8.5) at room temperature. The density of ALP staining was quantified by using Image J (National Institutes of Health, Bethesda, MD) software. For alizarin red staining, the cells were immersed in a 40 mM alizarin (Sigma-Aldrich) solution (pH 4.2) for 20 min at room temperature with gentle agitation. The solution then was removed, and the mineralized matrices were washed with water.

### Trichloroacetic acid (TCA) precipitation

To concentrate the BMP3 protein, TCA precipitation was performed on medium collected from W20-17 cells that were transfected with BMP3 expression vectors. A 25-ml volume of medium was collected, and 10 times the sample volume of 10% TCA was added and incubated on ice for 1.5 h. This was followed by centrifugation at  $4000 \times g$  for 15 min at 4 C. The TCA was aspirated, 400  $\mu$ l acetone was added, and the sample was vortexed vigorously and then centrifuged at  $12000 \times g$  for 10 min at 4 C. The acetone was aspirated, and the sample was dried at room temperature for 5 min. Finally, lysis buffer was added, and the sample incubated at 37 C for 5 min before Western blot analysis (38).

### Western blot analysis

The following antibodies were used for Western blot analysis: anti-BMP3 polyclonal antibody, anti-Acvr2b polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA), anti-phosphorylated Smad1/5/8 polyclonal antibody, anti-Smad1 polyclonal antibody (Cell Signaling, Beverly, MA), and anti- $\beta$ -actin mouse monoclonal antibody (Sigma-Aldrich). The target proteins were detected using a horseradish peroxidase-conjugated antimouse, antirabbit IgG antibody (Cell Signaling), or anti-goat IgG antibody (Santa Cruz). Protein levels were quantified using Image J software.

### Reverse transcription and quantitative PCR analysis

Total RNA was isolated from W20-17 cells using Trizol (Invitrogen, Carlsbad, CA) and then reverse transcribed into cDNA using Superscript III (Invitrogen). The cDNA was amplified by PCR using specific primers for murine osteocalcin (primer sequences: forward, agactccggcgctactctt; reverse, ctcgtcacaagcagggttaag), BMPR-II (primer sequences: forward, gagcctccttgacctg; reverse, gtagcagccccgtccaatc), Acvr2a (primer sequences: forward, ccctcctgtactgttctactca; reverse, gcaatggcttcaacctagt), Acvr2b (primer sequences: forward, tggctgttcggttgagc; reverse, ggcatgtaccgtctgtg), and  $\beta$ -actin. Quantitative real-time PCR was performed using the Roche (Indianapolis, IN) Light Cycler 480 Real-time PCR system with probe-based detection (Universal Probe Library; Roche). Values were normalized to  $\beta$ -actin using the 2- $\Delta\Delta$ Ct method (39).

### RNAi transfection

RNAi Stealth oligonucleotides were designed against murine Acvr2b (no. MSS201683; Invitrogen), and a scrambled RNAi was used as a negative control (Invitrogen). Cells were trans-



fected with siRNA using N-TER Nanoparticle siRNA Transfection System according to the manufacturer's instructions (Sigma-Aldrich).

### Statistical analysis

Comparisons were made using an unpaired Student's *t* test; the results are shown as means  $\pm$  SD. Statistical significance is indicated as  $P < 0.05$  or  $P < 0.01$ .

### Acknowledgments

Address all correspondence and requests for reprints to: Laura Gamer, Harvard School of Dental Medicine, Developmental Biology, 188 Longwood Avenue, Boston, Massachusetts 02115. E-mail: laura\_gamer@hsdm.harvard.edu.

This work was supported by Grant AR50174 from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH) (to V.R.).

Disclosure Summary: S.K., L.G., K.C., J.L., K.T., T.K., and V.R. have nothing to declare. R.R. was previously employed by Regeneron Pharmaceuticals and had equity interests in Regeneron Pharmaceuticals. A.E. is employed by Regeneron Pharmaceuticals and has equity interests in Regeneron Pharmaceuticals.

### References

1. Urist MR 1965 Bone: formation by autoinduction. *Science* 150: 893–899
2. Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V 1992 Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. *Endocrinology* 130:1318–1324
3. Yamaguchi A, Ishizuya T, Kintou N, Wada Y, Katagiri T, Wozney JM, Rosen V, Yoshiki S 1996 Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. *Biochem Biophys Res Commun* 220:366–371
4. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L, Einhorn T, Tabin CJ, Rosen V 2006 BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. *Nat Genet* 38:1424–1429
5. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T 1994 Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. *J Cell Biol* 127:1755–1766
6. Bianco P, Robey PG, Saggio I, Rinnucci M 2010 "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease. *Hum Gene Ther* 21:1057–1066
7. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS 2006 A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. *Nat Genet* 38:525–527
8. Fukuda T, Kohda M, Kanomata K, Nojima J, Nakamura A, Kamizono J, Noguchi Y, Iwakiri K, Kondo T, Kurose J, Endo K, Awakura T, Fukushi J, Nakashima Y, Chiyonobu T, Kawara A, Nishida Y, Wada I, Akita M, Komori T, Nakayama K, Nanba A, Maruki Y, Yoda T, Tomoda H, *et al.* 2009 Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. *J Biol Chem* 284:7149–7156
9. Katagiri T, Suda T, Miyazono K 2008 The bone morphogenetic proteins. New York: Cold Spring Harbor Press
10. Katagiri T, Imada M, Yanai T, Suda T, Takahashi N, Kamijo R 2002 Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. *Genes Cells* 7:949–960
11. Hollnagel A, Oehlmann V, Heymer J, R  ther U, Nordheim A 1999 Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. *J Biol Chem* 274:19838–19845
12. Alam N, St-Arnaud R, Lauzier D, Rosen V, Hamdy RC 2009 Are endogenous BMP necessary for bone healing during distraction osteogenesis? *Clin Orthop Relat Res* 467:3190–3198
13. Qiu T, Wu X, Zhang F, Clemens TL, Wan M, Cao X 2010 TGF- $\beta$  type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. *Nat Cell Biol* 12:224–234
14. Edwards JR, Nyman JS, Lwin ST, Moore MM, Esparza J, O'Quinn EC, Hart AJ, Biswas S, Patil CA, Lonning S, Mahadevan-Jansen A, Mundy GR 2010 Inhibition of TGF- $\beta$  signaling by 1D11 antibody treatment increases bone mass and quality in vivo. *J Bone Miner Res* 25:2419–2426
15. Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, Glatt V, Stadmeier L, Smith D, Seehra J, Bouxsein ML 2008 A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. *Proc Natl Acad Sci USA* 105:7082–7087
16. Perrien DS, Akel NS, Edwards PK, Carver AA, Bendre MS, Swain FL, Skinner RA, Hogue WR, Nicks KM, Pierson TM, Suva LJ, Gaddy D 2007 Inhibin A is an endocrine stimulator of bone mass and strength. *Endocrinology* 148:1654–1665
17. Dickman S 1998 Growing joints use their noggins. *Science* 280: 1350
18. Khokha MK, Hsu D, Brunet LJ, Dionne MS, Harland RM 2003 Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. *Nat Genet* 34:303–307
19. Daluiski A, Engstrand T, Bahamonde ME, Gamer LW, Agius E, Stevenson SL, Cox K, Rosen V, Lyons KM 2001 Bone morphogenetic protein-3 is a negative regulator of bone density. *Nat Genet* 27:84–88
20. Gamer LW, Cox K, Carlo JM, Rosen V 2009 Overexpression of BMP3 in the developing skeleton alters endochondral bone formation resulting in spontaneous rib fractures. *Dev Dyn* 238:2374–2381
21. Paic F, Igwe JC, Nori R, Kronenberg MS, Franceschetti T, Harrington P, Kuo L, Shin DG, Rowe DW, Harris SE, Kalajic I 2009 Identification of differentially expressed genes between osteoblasts and osteocytes. *Bone* 45:682–692
22. Gamer LW, Nove J, Levin M, Rosen V 2005 BMP-3 is a novel inhibitor of both activin and BMP-4 signaling in *Xenopus* embryos. *Dev Biol* 285:156–168
23. Allendorph GP, Isaacs MJ, Kawakami Y, Izipisua Belmonte JC, Choe S 2007 BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. *Biochemistry* 46:12238–12247
24. Yeh LC, Tsai AD, Zavala MC, Lee JC 2004 Cartilage-derived morphogenetic proteins enhance the osteogenic protein-1-induced osteoblastic cell differentiation of C2C12 cells. *J Cell Physiol* 201: 401–408
25. de Jong DS, van Zoelen EJ, Bauerschmidt S, Olijve W, Steegenga WT 2002 Microarray analysis of bone morphogenetic protein, transforming growth factor  $\beta$ , and activin early response genes during osteoblastic cell differentiation. *J Bone Miner Res* 17:2119–2129
26. Gamer LW, Tsuji K, Cox K, Capelo LP, Lowery J, Beppu H, Rosen V 2011 BMP-2 is dispensable for formation of the limb skeleton. *Genesis* 49:719–724

27. Koncarevic A, Cornwall-Brady M, Pullen A, Davies M, Sako D, Liu J, Kumar R, Tomkinson K, Baker T, Umiker B, Monnell T, Grinberg AV, Liharska K, Underwood KW, Ucran JA, Howard E, Barberio J, Spaits M, Pearsall S, Seehra J, Lachey J 2010 A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. *Endocrinology* 151:4289–4300
28. Valenzuela DM, Murphy AJ, Frendewey D, Gale NW, Economides AN, Auerbach W, Poucymirou WT, Adams NC, Rojas J, Yasenchak J, Chernomorsky R, Boucher M, Elsasser AL, Esau L, Zheng J, Griffiths JA, Wang X, Su H, Xue Y, Dominguez MG, Noguera I, Torres R, Macdonald LE, Stewart AF, DeChiara TM, Yancopoulos GD 2003 High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. *Nat Biotechnol* 21:652–659
29. Colnot C, Huang S, Helms J 2006 Analyzing the cellular contribution of bone marrow to fracture healing using bone marrow transplantation in mice. *Biochem Biophys Res Commun* 350:557–561
30. Goldman LA, Cutrone EC, Kotenko SV, Krause CD, Langer JA 1996 Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. *Biotechniques* 21:1013–1015
31. Nojima J, Kanomata K, Takada Y, Fukuda T, Kokabu S, Ohte S, Takada T, Tsukui T, Yamamoto TS, Sasanuma H, Yoneyama K, Ueno N, Okazaki Y, Kamijo R, Yoda T, Katagiri T 2010 Dual roles of smad proteins in the conversion from myoblasts to osteoblastic cells by bone morphogenetic proteins. *J Biol Chem* 285:15577–15586
32. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, Kuhstoss SA, Thomas CC, Schipani E, Baron R, Bringham FR, Kronenberg HM 2010 Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. *Cell Metab* 11:161–171
33. Kokabu S, Nojima J, Kanomata K, Ohte S, Yoda T, Fukuda T, Katagiri T 2010 Protein phosphatase magnesium-dependent 1A-mediated inhibition of BMP signaling is independent of Smad dephosphorylation. *J Bone Miner Res* 25:653–660
34. Kanomata K, Kokabu S, Nojima J, Fukuda T, Katagiri T 2009 DRAGON, a GPI-anchored membrane protein, inhibits BMP signaling in C2C12 myoblasts. *Genes Cells* 14:695–702
35. Fukuda T, Kokabu S, Ohte S, Sasanuma H, Kanomata K, Yoneyama K, Kato H, Akita M, Oda H, Katagiri T 2010 Canonical Wnts and BMP cooperatively induce osteoblastic differentiation through a GSK3 $\beta$ -dependent and  $\beta$ -catenin-independent mechanism. *Differentiation* 80:46–52
36. Kokabu S, Ohte S, Sasanuma H, Shin M, Yoneyama K, Murata E, Kanomata K, Nojima J, Ono Y, Yoda T, Fukuda T, Katagiri T 2011 Suppression of BMP-Smad signaling axis-induced osteoblastic differentiation by small C-terminal domain phosphatase 1, a Smad phosphatase. *Mol Endocrinol* 25:474–481
37. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC 2002 Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. *Endocrinology* 143:74–83
38. Hileman SM, Tornøe J, Flier JS, Bjørbaek C 2000 Transcellular transport of leptin by the short leptin receptor isoform ObRa in Madin-Darby Canine Kidney cells. *Endocrinology* 141:1955–1961
39. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C_T}$  method. *Methods* 25:402–408



You can share your expertise or find career advice  
through the **Mentor Exchange**.

[www.endo-society.org/mentor](http://www.endo-society.org/mentor)